IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on discovering, developing, and commercializing cancer therapies. The company uses small-molecule drug discovery, structural biology, and bioinformatics, along with internal capabilities in identifying and validating translational biomarkers, to develop targeted therapies aligned with the genetic drivers of disease. IDEAYA Biosciences has a pipeline of product candidates concentrating on synthetic lethality and antibody-drug conjugates (ADCs) for solid tumor indications defined at the molecular level. Their clinical development strategy involves evaluating product candidates in rational combinations and earlier in the course of disease in adjuvant and neoadjuvant settings. The current clinical pipeline includes nine potential first-in-class product candidates across four clinical focus areas: (1) Darovasertib for Uveal Melanoma; (2) ADC and DNA Damage Response (DDR) Combinations; (3) MTAP Pathway; and (4) Next Generation Therapies. The company has collaborations with pharmaceutical companies to support its clinical development activities, including agreements with Pfizer, Servier, Hengrui Pharma, and Gilead. Darovasertib, an oral, potent, and selective small molecule inhibitor of protein kinase C (PKC), is IDEAYA Biosciences' most advanced clinical program. It is being developed for uveal melanoma (UM), a rare and aggressive ocular cancer where approximately 95% of patients have activating mutations in GNAQ/11 GTPase proteins that drive PKC signaling and tumor cell growth. The company is conducting multiple clinical trials for darovasertib in both metastatic and pre-metastatic settings of UM.